GC
KRTX

Guggenheim Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Guggenheim Capital’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,495
Closed -$2.06M – 1959
2023
Q4 		$2.06M Sell
6,495
-573
-8% -$111K 0.02% 839
2023
Q3 		$1.2M Buy
7,068
+345
+5% +$64.9K 0.01% 1025
2023
Q2 		$1.46M Sell
6,723
-188
-3% -$40.3K 0.01% 988
2023
Q1 		$1.26M Sell
6,911
-4,186
-38% -$801K 0.01% 1061
2022
Q4 		$2.18M Buy
11,097
+2,035
+22% +$436K 0.02% 823
2022
Q3 		$2.04M Sell
9,062
-433
-5% -$87.6K 0.02% 831
2022
Q2 		$1.2M Sell
9,495
-575
-6% -$66.1K 0.01% 1142
2022
Q1 		$1.28M Buy
10,070
+549
+6% +$61.8K 0.01% 1234
2021
Q4 		$1.25M Buy
9,521
+412
+5% +$53.2K 0.01% 1271
2021
Q3 		$1.11M Sell
9,109
-212
-2% -$24.5K 0.01% 1361
2021
Q2 		$1.06M Buy
9,321
+426
+5% +$49.8K 0.01% 1458
2021
Q1 		$1.07M Buy
8,895
+4,242
+91% +$481K 0.01% 1365
2020
Q4 		$473K Buy
+4,653
New +$431K ﹤0.01% 1661

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Guggenheim Capital's KRTX Position: Q1 2024 in Review

Guggenheim Capital sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 6,495 shares — an estimated $2.06M sold.

Guggenheim Capital first reported a position in KRTX in Q4 2020 and held it in 13 quarters. The position peaked at $2.18M in Q4 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Guggenheim Capital reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Guggenheim Capital sold 6,495 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.06M.
  • Guggenheim Capital first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • Guggenheim Capital's Karuna Therapeutics, Inc. Common Stock position peaked at $2.18M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Guggenheim Capital's 13F filing for Q1 2024, filed 14 May 2024.